No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARVN240621C30000
- 3.96
- -3.84-49.23%
15min DelayClose May 31 15:59 ET
3.96High3.96Low
3.96Open7.80Pre Close1 Volume6 Open Interest30.00Strike Price396.00Turnover77.49%IV3.20%PremiumJun 21, 2024Expiry Date3.14Intrinsic Value100Multiplier19DDays to Expiry0.82Time Value100Contract SizeAmericanOptions Type0.7470Delta0.0544Gamma7.89Leverage Ratio-0.0525Theta0.0108Rho5.89Eff Leverage0.0243Vega
Intraday
- 5D
- 1D
News
Express News | Arvinas- Due to Hsr Termination & Satisfaction of Closing Conditions of License Agreement, Asset Agreement, Novartis Pharma AG to Pay Co $150.0 Mln
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 c
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 1.65 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 50,000 shares of its common stock on May 20, with a total market value of approximately $1.65 million. Sean Ca
Buy Rating Affirmed for Arvinas Holding Company on Strong Clinical Trial Results and Competitive Market Positioning
Express News | HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
Comments
Arvinas' high P/S ratio could be worrisome as revenue forecasts are not promising. The anticipated future revenues may not sustain the current positive sentiment. Without significant improvements, these prices may not be deemed reasonable.
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28% 1
Sean Cassidy expressed confidence in the company's future and the promising clinical development and commercial opportunity for the PROTAC(R) protein degrader pipeline. The company's leadership acknowledged Cassidy's pivotal role in creating Arvinas' strong financial profile.
1
$Arvinas(ARVN.US$ 👀 new hoy
$Arvinas(ARVN.US$ I hope everyone bought that sub 14 dip! This thing has been a beast.
1
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more